Kornimate/medical-research-clean huggingface dataset:
a mammography fasttrack program in increasing the number of women undergoing breast cancer screening

Conditions: Breast Cancer

Summary: rationale: screening may help doctors find breast cancer cells early and plan better treatment for breast cancer. the mammography fasttrack program may be effective in increasing the number of patients who undergo mammography. purpose: this randomized clinical trial is studying the use of a mammography fasttrack program to increase the number of women who undergo mammography.

objectives: * classify all patients within the massachusetts general primary care-practice based research network (mgpc-pbrn) according to patient-primary care provider (pcp) linkage status. * develop a breast cancer screening intervention program called mammography fasttrack that facilitates the ordering of mammograms to be used either by pcps (for pcp-linked patients) or by practice managers (for practice-linked patients). * compare the impact of the mammography fasttrack program on mammography screening rates in pcp-linked vs practice-linked patients overdue for breast cancer screening. outline: this is a randomized, multicenter study. mammography-eligible women are linked to either a provider or a practice within the massachusetts general primary care practice-based research network (mgpc-pbrn). practices within the mgpc-pbrn are stratified according to baseline mammography screening rates (high vs low) and practice type (community health center vs hospital-based vs community-based) and are randomized to 1 of 2 arms. * arm i: physicians and practice managers receive e-mail alerts at months 1 and 3 informing them of the availability of mammography screening data for their panel of primary-care patients. a hyperlink refers the provider to a web-portal for the mammography fasttrack program that lists all eligible patients who have not undergone mammography. the provider may then click a button to schedule, defer (providing reason for deferral), or provide the date of a recent mammogram. * arm ii: practices continue standard care. at the end of 12 months, electronic report and billing data and a review of electronic health records are used to determine the completion of mammograms. projected accrual: a total of 6,730 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * any outpatient at a participating massachusetts general primary care practice-based research network (mgpc-pbrn) practice within the past 3 years * no patient who the massachusetts general hospital system lists as having a primary care provider who is not in one of the mgpc-pbrn networks (linking patients with a provider or practice) * no patient who is not linked to specific provider or practice (randomized portion of study) * billing, scheduling, and clinical electronic data sources required * no mammogram within the past 2 years (randomized portion of study) * hormone receptor status not specified patient characteristics: * age 42 to 69 years (randomized portion of study) * female * menopausal status not specified prior concurrent therapy: * no prior bilateral mastectomy (randomized portion of study)

Keywords: breast cancer
assessment of different clinical techniques to treat patients with chronic low back pain

Conditions: Chronic Low Back Pain (CLBP)

Summary: this clinical trial aims to assess the effectiveness of different clinical techniques in treating patients with chronic low back pain (clbp). two test groups will be included: one receiving conventional therapy (nsaids and other physical therapy techniques) and the other receiving a combination of neuromodulation and platelet-rich plasma (prp) therapy. chronic pain, persisting for more than three months, inhibits natural pathways like gaba and promotes excitatory pathways, leading to increased inflammation. the study hypothesizes that neuromodulation via the dorsal root ganglion (drg) and prp therapy will provide superior pain relief and functional improvement compared to conventional therapy.

chronic low back pain (clbp) affects millions of individuals worldwide, significantly impacting quality of life and productivity. traditional treatments often involve nsaids and physical therapy, but these methods sometimes fail to provide adequate relief. chronic pain is characterized by prolonged activation of the central and peripheral nervous systems, resulting in sensitization and increased pain perception. the current study will evaluate two treatment modalities: 1. conventional therapy: this includes the use of nonsteroidal anti-inflammatory drugs (nsaids) and other standard physical therapy techniques. 2. neuromodulation + prp therapy: neuromodulation is performed via the drg to modulate excitatory pathways, with medial sensory nerves being desensitized at 42°c for 3-20 minutes. prp therapy involves the injection of concentrated platelets to promote healing and reduce inflammation. the study will provide valuable insights into the comparative effectiveness of these treatments, potentially guiding future therapeutic strategies for clbp.

Eligibility criteria:
inclusion criteria: * adults aged 40-60 years. * diagnosed with chronic low back pain persisting for more than three months. * willingness to participate and comply with study procedures. * ability to provide informed consent. exclusion criteria: * comorbidities. * contagious and non-contagious infections * known hypersensitivity to study interventions. * presence of severe psychiatric disorders. * pregnancy or breastfeeding. * participation in another clinical trial within the last 30 days.

Keywords: clbp neuromodulation prp
delivering a digital health intervention to improve food access and dietary quality among adults with hypertension

Conditions: Hypertension

Summary: a total of 65 participants with hypertension and low access to high quality food will be enrolled to test the feasibility of using commercially available grocery delivery services, simultaneous to a robust behavioral intervention, to improve adherence to the dietary approaches to stop hypertension (dash) eating pattern. the behavioral intervention will include skills training, nutrient goal setting, self-monitoring via dietary tracking, personalized text message feedback, and adaptive health coaching. participants will also receive a membership to instacart+ and weekly grocery list recommendations from a health coach. the primary outcome will be indicators of feasibility, including acceptability, demand, implementation and practicality and adaption. change in dash adherence and blood pressure will also be evaluated. the intervention period for participants will be 4 months.


Eligibility criteria:
inclusion criteria: * adult 18 years of age or older * has hypertension, defined as a systolic bp of 130-159 mmhg and/or diastolic bp of 80-99 mmhg, whether or not taking hypertension medication. * resides in a census tract defined as low access by the united states department of agriculture (usda) * resides in a zip code serviced by the grocery delivery app * bmi 18.5 kg/m2+ * has a smartphone with a data plan * willing to receive daily text messages * can participate in online videoconference visits * can read and write in english exclusion criteria: * participating in another related research study * cardiovascular disease event in the last 6 months * active cancer * recent hospitalization due to psychiatric condition or event * pregnancy or planned during the study period * bmi 37 kg/m2 or higher * documented dementia * on kidney dialysis * instructed to eat a low potassium diet * planned or recent bariatric surgery

Keywords: digital health health behavior nutrition hypertension food access
a treatment protocol for expanded access administration of prometic plasminogen due to closure of clinical trial

Conditions: Hypoplasminogenemia

Summary: the clinical trial is no longer enrolling and is currently closing and prometic will continue to provide plasminogen (human) under a treatment protocol to subjects in the united states (us) with hypoplasminogenemia requiring plasminogen replacement therapy who completed the end of study visit in the following prometic-sponsored clinical trials: 2002c011g, 2002c013g, 2002c016g, 2002c017g and 2002c019g.

us adult and pediatric subjects with hypoplasminogenemia requiring plasminogen replacement therapy who completed the end of study visit in the following prometic-sponsored clinical studies: 2002c011g, 2002c013g, 2002c016g, 2002c017g and 2002c019g will continue to receive their repeat-dose study of plasminogen (human) under a treatment protocol. approximately, 15 subjects will be enrolled in the treatment protocol under an expanded access to continue to receive plasminogen (human) at a dose of 6.6 mg/kg as a 10 to 30-minute intravenous (iv) infusion at site visits or at home by either the subject or caregiver at the same frequency as in their prior prometic-sponsored clinical study. subjects or caregivers may be trained for study drug administration as deemed appropriate by the investigator. dosing frequency will be adjusted by the investigator based on clinical response and plasminogen activity trough levels. subjects who completed the end of study visit in studies 2002c011g, 2002c013g, 2002c016g, 2002c017g and 2002c019g and signed informed consent (and assent, if applicable) for the present study will be enrolled in this study; this visit will be designated as day 1 of the present study. subjects will return to their study site every 26 weeks, or more often as determined by the investigator, for safety assessments and measurements of plasminogen activity trough levels at the investigator's discretion. treatment with plasminogen (human) will continue until the product has been approved and is commercially available or discontinued at any time by the sponsor or at the discretion of the investigator.

Eligibility criteria:
inclusion criteria: * subjects must meet all the criteria below to participate in this study: 1. the subject or the subject's caregiver has provided informed consent (as well as assent by subjects with ages dictated by local investigational review board \[irb\] guidelines). 2. subject has a diagnosis of hypoplasminogenemia requiring replacement therapy with plasminogen (human). 3. subject has completed the end of study visit at a united states site in the following prometic-sponsored clinical studies: 2002c011g, 2002c013g, 2002c016g, 2002c017g and 2002c019g. 4. female and male subject agrees to use contraceptive methods from day 1 through 14 days after last dose of study treatment (unless documented as biologically or surgically sterile \[e.g., postmenopausal, vasectomized\]), or has not reached reproductive age. exclusion criteria: * subjects who are pregnant and/or lactating are excluded from participating in the study.
interactions between striatum and cerebellum in adcy5 and prrt2 dystonias

Conditions: Dystonia

Summary: the investigators will study the relationship between the basal ganglia and the cerebellum in dystonia by associating cerebellar stimulations with functional magnetic resonance imaging analysis.

although dysfunctions in both basal ganglia and cerebellum in dystonia are well documented, the functional relationships between these two important motor control networks remains unclear in the context of dystonia. here the investigators propose to tackle this issue by associating cerebellar stimulations with functional analysis using fmri in dystonic patients. the working hypothesis is that the primary torsion dystonia (ptd) pathophysiology involves dysfunction of striatum that is amplified by dysregulation of the cerebello-thalamo-striatal pathway. the project is to study dystonia forms resulting primarily from dysfunctions of the striatum (patients with mutation of the adcy5 gene) and compare them with patients with putative dysfunction of the cerebellum (patients with mutation of the prrt2 gene) and healthy controls. in these patients, the investigators will look for (1) how cerebello-thalamo striatal pathway can be influenced by striatal dysfunctions and (2) whether cerebellar stimulation may prevent (or worsen?) the disrupted activity in the basal ganglia and (3) whether striatum-related dystonia share the same abnormal network with another form of dystonia resulting from another dysfunction (patients with prrt2 mutation).

Eligibility criteria:
inclusion criteria: * clinical diagnosis of dystonia * characterized adcy5 or prrt2 mutation * must have a european social security card or a parent having an european social security card * must be older than \> 15 years 3 months * must be able to give informed consent or, for minor patients, parents must be able to give informed consent * must be able to comply with all study procedures, based on the judgment by the investigator(s). exclusion criteria: * major depression or any major mental disorders (axis i disorders) * neurologic disorder other than dystonia * presence of pacemaker, intracardiac lines, implanted pumps or stimulators, or metal objects inside the eye or skull, cochlear implant * permanent makeup of lips or eyelids * black large tattoo close to the head * severe claustrophobia * current pregnancy or breast feeding * copper intrauterine device subjects with one of the following exclusion criteria will not receive cerebellar stimulation * open scalp wounds or scalp infection, * epilepsy or seizures * taking at the time of the study: ketamine, antidepressants, ganciclovir, ritonavir, amphetamines, antiemetic.

Keywords: cerebellum striatum human fmri transcranial magnetic stimulation genetic dystonia
association between mortality and diabetes in elderly koreans: the south-west seoul (sws) study

Conditions: Apparently Healthy Elderly People; (Between 60-92 Years of Age)

Summary: diabetes mellitus is known to increase the risk of premature death in the general population. in this study, the investigators examine the impact of body mass index (bmi) levels, waist circumference, and presence/absence of diabetes on all-cause and cardiovascular mortality in elderly koreans.

the investigators analyze follow-up data from the south-west seoul (sws) study, a prospective observational cohort study of an elderly korean population residing in seoul, the metropolitan capital city of korea. briefly, the study population was selected from four urban districts (guro, yangcheon, gwanak and gangseo) located in the south-west area of seoul. a total of 1737 apparently healthy individuals (between 60 and 92 years of age) eventually participated in this survey starting in 1999. a follow-up examination was performed in 2002, and an additional 873 subjects who had not participated in the first examination were newly recruited. after a median follow-up of 10 years, each subject's vital status or cause of death as of 31 december 2011 was determined after linking these cohort data with death certificate data from the korean national statistical office. terminology and codes from the international classification of disease, tenth revision (icd-10), were used to classify the underlying cause of death due to cardiovascular disease (icd-10 codes i00-i79), cancer (icd-10 codes c00-c97) and others.

Eligibility criteria:
inclusion criteria: * apparently healthy individuals * over the age of 60 years exclusion criteria: * those with a mismatched identification number * missing data regarding bmi, waist circumference, and presence of diabetes
a trial of cm-at in children with autism- open label extension study

Conditions: Autism

Summary: the purpose of this study is to determine whether cm-at is effective in treating the core symptoms of autism.

autism is currently a significant cause of disability in the pediatric population. cm-at is based upon the observation that many children with autism do not digest protein. cm-at is a proprietary enzyme that is designed as a powder taken three times a day. it is formulated to be released in the small intestine to enhance protein digestion thus increasing the availability of essential amino acids.

Eligibility criteria:
inclusion criteria: * meets the current diagnostic and statistical manual for mental disorders (dsm-iv-tr) diagnostic criteria for autistic disorder (ad) * ongoing 00102 protocol required completion of 00101 protocol * now recruiting subjects directly into 00102 protocol exclusion criteria: * ongoing study required patients to be 3-8 years old weighing \< 11kg (24.2 lbs.), and achieving ages 9-12 years old weighing \< 22kg (48.4 lbs.). * newly recruited subjects must be between ages 9 - 12 years old weighing \< 22kgs (48.4 lbs.) * demonstrated previous allergy to porcine (pork) products * previous history of severe head trauma or stroke, seizure within one year of entering study or uncontrolled systemic disease * diagnosis of: hiv, cerebral palsy, endocrine disorder, pancreatic disease * within 30 days of starting the study, certain supplementation, chelation or dietary restriction (a 30 day washout period would be required for inclusion) * any use of psychotropic medications, stimulants, or ssri's must be discontinued for 30 days prior to entrance

Keywords: autism
a clinical trial of tqc3927 powder for inhalation in chronic obstructive pulmonary disease

Conditions: Chronic Obstructive Pulmonary Disease

Summary: this project is the stage of dose escalation, is was divided into single and multiple dose clinical study, this is a multi-center, randomized, double-blind, placebo-controlled , study to the safety, tolerability and pharmacokinetic characteristics of tqc3927 powder for inhalation in chronic obstructive pulmonary disease


Eligibility criteria:
inclusion criteria: * between 18 and 45 years (inclusive)，both male and female * the subjects were able to undergo reproducible fev1 lung function testing according to the american thoracic society/european respiratory society (ats/ers) 2005 standard during screening * subject should weigh at least 45kg. and body mass index (bmi) within 18\~30 kg/m2 * have no pregnancy plan and voluntarily take effective contraception measures from time of screening to at least 90 days after the last dose (subjects and their partners) exclusion criteria: * patients with a history of glaucoma, functional constipation, prostate hyperplasia, urinary tract obstruction, etc * individuals with a history of illegal drug abuse or who have tested positive for drug abuse screening during the screening period (including benzodiazepines, methamphetamine, cocaine, morphine, ketamine, tetrahydrocannabinol) * participated in other clinical trials and received research interventions in the 3 months prior to participating in this trial * screening for individuals who have used biologics within the past 3 months * individuals who have lost blood or donated more than 400 ml of blood within 3 months prior to the experiment, or who have received blood transfusions or used blood products * any clear history of drug or food allergies, especially those who are allergic to ingredients similar to the investigational drug * screening for individuals who have frequently consumed alcohol within the previous 6 months (i.e. females consume more than 14 standard units of alcohol per week, males consume more than 21 standard units of alcohol per week (1 standard unit contains 14g of alcohol, such as 360 ml beer or 45 ml of 40% alcohol strong liquor or 150 ml wine) or are unable to abstain from alcohol during the trial period; or those who test positive for alcohol breath test * history of any malignant tumors in organs or systems within the past 5 years, regardless of whether they have received treatment or not, except for local basal cell carcinoma of the skin * when screening, the sitting systolic blood pressure should be ≥ 160 mmhg, and the sitting diastolic blood pressure should be ≥ 100 mmhg; pulse rate\ 100 bpm * clinically significant apnea patients requiring continuous positive airway pressure (cpap) or non-invasive positive airway pressure (nippv) devices * those who require long-term oxygen therapy (oxygen therapy time\>15 hours/day) * individuals who have undergone lobectomy or lung volume reduction surgery within the 12 months prior to the start of the study
autogenic inhibition versus reciprocal inhibition muscle energy techniques effect on swimming performance on swimmers with scapular dyskinesis

Conditions: Scapular Dyskinesis

Summary: swimming can cause shoulder pain due to scapular dyskinesis. proper scapula movement is necessary for efficient swimming strokes and to avoid injury. studying the effects of autogenic and reciprocal inhibition muscle energy techniques on swimmers with scapular dyskinesis can lead to effective interventions and reduce shoulder injuries

efficient swimming strokes require proper positioning of the scapula. scapular dyskinesis (sd) is a condition where normal scapular kinematics are altered due to injury or changes in muscle activation. swimmers, who are considered overhead athletes, have risk of developing sd. even individuals who do not experience symptoms can have sd, and it may lead to future shoulder injuries. early diagnosis and treatment of this condition can prevent it from progressing and minimize the risk of injury. additionally, using autogenic and reciprocal inhibition muscle energy techniques can enhance the activation of the appropriate muscles responsible for scapular movement, which can lead to more effective interventions, improved swimming performance, and reduced injury risk. he intervention protocol (muscle energy techniques to the upper fibers of the trapezius, levator scapulae, pectoralis major, latissimus dorsi) will be conducted for 8-14 minutes over 3 weeks with 12 sessions/4 times a week. outcomes measure will be assessed after the intervention period and data will be analyzed.

Eligibility criteria:
inclusion criteria: * swimmers with at least four times training per week * does not have any shoulder pain or injury or operation to the shoulders * positive scapular dyskinesis diagnosis test * freestyle (also known as a front crawl) swimming stroke exclusion criteria: * shoulder pain in the last six months * history of shoulder surgery or fracture within the last six months * frequent practice of physical activity in any other sport * negative result of the scapular dyskinesis test * other swimming strokes

Keywords: scapular dyskinesis, autogenic inhibition, reciprocal inhibition, muscle energy technique
transcranial stimulation for upper limb training of individuals with sequelae from intracranial hemorrhage

Conditions: Cerebrovascular Disorders

Summary: the purpose of this study is to investigate the effect of transcranial stimulation for upper limb training of patients with sequelae from an intracranial hemorrhage. patients receive five days of upper limb occupational therapy training in combination with real or sham stimulation. patients complete the jebsen taylor hand function test before, after and 7 days later. the intervention takes place at patients' home address.

aim: to investigate the effect of anodal transcranial direct current stimulation (tdcs) for upper limb training of individuals with sequelae from intracranial hemorrhage. design: triple-blinded randomised controlled trial study population: patients with intracranial hemorrhage (ich) of non-traumatic aetiology. between 6 months and five years from injury. intervention: group 1 receive five days of upper limb occupational therapy in combination with anodal stimulation group 2 receive five days of upper limb occupational therapy in combination with sham stimulation the intervention takes place at patients' home address. assessment tool: patients complete the jebsen taylor hand function test at baseline, post-intervention and at 7 days follow-up.

Eligibility criteria:
inclusion criteria: * intracranial hemorrhage * injury between 6 months and 5 years exclusion criteria: * traumatic brain injury * other neurological disorders * epilepsy * metal implants in the head

Keywords: transcranial stimulation intracranial hemorrhage home training occupational therapy jebsen taylor hand function test